thyroid pharmacology

42
Thyroid pharmacology

Upload: faris

Post on 11-Jan-2016

72 views

Category:

Documents


0 download

DESCRIPTION

Thyroid pharmacology. THYROID GLAND. Location 12 to 20 g in size In neck, anterior to trachea Between cricoid cartilage and suprasternal notch Highly vascular and soft in consistency. THYROID GLAND. Consists of two lobes Connected by an isthmus 4 parathyroid glands - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Thyroid pharmacology

Thyroid pharmacology

Page 2: Thyroid pharmacology

THYROID GLAND

Location

• 12 to 20 g in size

• In neck, anterior to trachea

• Between cricoid cartilage and suprasternal notch

• Highly vascular and soft in consistency.

Page 3: Thyroid pharmacology

THYROID GLAND

Consists of two lobes

• Connected by an isthmus

• 4 parathyroid glands

– Posterior region of each pole

• Laryngeal nerves traverse lateral borders of gland

Page 4: Thyroid pharmacology

Secretions

Produces two related hormones

• Thyroxine (T4)

• Triiodothyronine (T3)

Page 5: Thyroid pharmacology

Action

Play a critical role in

• Cell differentiation during development

• Help to maintain thermogenic and metabolic homeostasis in adult.

• Act through nuclear hormone receptors to modulate gene expression

Page 6: Thyroid pharmacology

Regulation of thyroid hormone synthesis

T4 and T3 feed back to inhibit

• Hypothalamic production of thyrotropin-releasing hormone (TRH)

• Pituitary production of thyroid-stimulating hormone (TSH)

Page 7: Thyroid pharmacology

TSH-R, thyroid-stimulating hormone receptor, Tg- thyroglobulinNIS - sodium-iodide symporter; TPO- thyroid peroxidaseDIT - di-iodotyrosine; MIT - monoiodotyrosine

Page 8: Thyroid pharmacology

Thyroid Hormone Synthesis

Thyroid hormones are derived from thyroglobulin• Large iodinated glycoprotein

After secretion into the thyroid follicle• Tg is iodinated on selected tyrosine residues that are

subsequently coupled via an ether linkage• Reuptake of Tg into thyroid follicular cell allows

proteolysis and the release of T4 and T3.

Page 9: Thyroid pharmacology

Iodine Metabolism and Transport • Iodide uptake is a critical first step in thyroid

hormone synthesis

• Ingested iodine is bound to serum proteins (particularly albumin)

• Unbound iodine is excreted in urine

• Iodine extracts from circulation in a highly efficient manner– 10 to 25% of radioactive tracer (e.g., 123I) is taken up by

the normal thyroid gland over 24 h; this value can rise to 70 to 90% in Graves' disease.

Page 10: Thyroid pharmacology

Na+/I- symporter (NIS)

• Mediate Iodide uptake • Expressed at basolateral membrane of thyroid

follicular cells.• Expressed

– Most highly in thyroid gland– Low levels in salivary glands, lactating breast, placenta

• Low I2 levels increase amount of NIS & stimulate uptake

• High I2 levels suppress NIS expression & uptake

Page 11: Thyroid pharmacology

Selective expression of NIS in thyroid allows

– Treatment of hyperthyroidism– Isotopic scanning– Abolition of thyroid cancer with radioisotopes of iodine

Without significant effects on other organs

Mutation of the NIS gene is a rare cause of congenital hypothyroidism

Page 12: Thyroid pharmacology

Oranification

• Iodide enters thyroid

• Trapped and transported to apical membrane of thyroid follicular cells

• Oxidized in an organification reaction (Tyroid PerOxidase & H2O2

)

Page 13: Thyroid pharmacology

Coupling

Reactive iodine atom is added to selected tyrosyl residues within Tyroglobulin

Iodotyrosines in Tg are then coupled via an ether linkage in a reaction Catalyzed by TPO

Either T4 or T3 can be produced by this reaction• Depending on number of iodine atoms present in

iodotyrosines.

Page 14: Thyroid pharmacology

Storage, Release• After coupling, Tg is taken back into thyroid cell

• It is processed in lysosomes to release T4 and T3

• Uncoupled mono- and diiodotyrosines (MIT, DIT) are deiodinated by enzyme dehalogenase

• Recycling any iodide that is not converted into thyroid hormones

Page 15: Thyroid pharmacology

Factors Influence Synthesis and Release

TSH is the dominant hormonal regulator of thyroid gland growth and function

Variety of growth factors, most produced locally in thyroid gland, also influence synthesis

• Insulin-like growth factor I (IGF-I• Epidermal growth factor• Transforming growth factor β (TGF- β)• Endothelins• Various cytokines.

Page 16: Thyroid pharmacology

• Disorders of thyroid hormone synthesis– Rare causes of congenital hypothyroidism

• Majority of disorders due to recessive mutations in TPO or Tg

• Defects also identified in– TSH-R– NIS– Pendrin anion transporter

• Transports I2 from cytoplasm to follicle lumen– H2O2 generation– Dehalogenase

Page 17: Thyroid pharmacology

• Biosynthetic defect of thyroid hormone

• Inadequate amounts of hormone

• Increased TSH synthesis

• Goiter

Page 18: Thyroid pharmacology

Transport And Metabolism

• T4 is secreted from the thyroid gland in at least 20-fold excess over T3

Both circulate bound to plasma proteins

• Thyroxine-binding globulin (TBG)

• Transthyretin (TTR), formerly known as thyroxine-binding prealbumin (TBPA)

• Albumin

Page 19: Thyroid pharmacology

Functions of serum-binding proteins

• Increase pool of circulating hormone

• Delay hormone clearance

• Modulate hormone delivery to selected tissue sites

Page 20: Thyroid pharmacology

Con. of TBG is relatively low (1 to 2 mg/dL)

• High affinity for thyroid hormones (T4 > T3), it carries about 80% of bound hormones

Albumin has relatively low affinity for thyroid hormones (high plasma con ~3.5 g/dL)

• It binds up to 10% of T4 and 30% of T3.

TTR carries about 10% of T4 but little T3.

Page 21: Thyroid pharmacology

• ≈ 99.98% of T4 and 99.7% of T3 are protein-bound

• T3 is less tightly bound than T4

• Amount of free T3 > free T4

Unbound (free) cons

• T4 ~2 1011 M

• T3 ~6 1012 M

Page 22: Thyroid pharmacology
Page 23: Thyroid pharmacology

Deiodinases• In many respects, T4 may be thought of as a

precursor for more potent T3

• T4 is converted to T3 by the deiodinase enzymes

Type I deiodinase• Located primarily in thyroid, liver, kidney• Has a relatively low affinity for T4

Type II deiodinase• Higher affinity for T4 • Found primarily in pituitary gland, brain, brown fat,

thyroid gland

Page 24: Thyroid pharmacology
Page 25: Thyroid pharmacology

T4 - T3 conversion may be impaired by

• Fasting

• Acute trauma

• Oral contraseptive agents

• Propylthiouracil

• Propranolol

• Amiodarone

• Glucocorticoids

Page 26: Thyroid pharmacology

THYROID HORMONE ACTION

• Act by binding to nuclear receptors, termed thyroid hormone receptors (TRs) ά and β

• Both ά and β are expressed in most tissues

• Both receptors are variably spliced to form unique isoforms

Page 27: Thyroid pharmacology

Thyroid hormone receptors ά

Highly expressed in– Brain– Kidney– Gonads– Muscle– Heart

• TR ά 2 isoform contains a unique carboxy terminus that prevents thyroid hormone binding

• It may function to block actions of other TR isoforms

Page 28: Thyroid pharmacology

Thyroid hormone receptors β

Highly expressed in– Pituitary– Liver

TR β 2 isoform• Has a unique amino terminus• Selectively expressed in hypothalamus & pituitary• Play a role in feedback control of thyroid axis

Page 29: Thyroid pharmacology

(1) T4 or T3 enters the nucleus(2) T3 binding dissociates CoR from TR(3) Coactivators (CoA) are recruited to the T3-bound receptor(4) gene expression is altered

Page 30: Thyroid pharmacology

Thyroid Hormone Resistance (RTH)

An autosomal dominant disorder characterized by

• Elevated free thyroid hormone levels• Inappropriately normal or elevated TSH

• Individuals with RTH (in general) do not exhibit signs and symptoms that are typical of hypothyroidism

• Apparently hormone resistance is compensated by increased levels of thyroid hormone

Page 31: Thyroid pharmacology

HYPOTHYROIDISM

• Worldwide most common cause of hypothyroidism - Iodine deficiency

Other causes

• Autoimmune disease (Hashimoto's thyroiditis)

• Iatrogenic causes (treatment of hyperthyroidism)

Page 32: Thyroid pharmacology

Treatment

• T4 - 10 to 15 ug/kg/ day• Dose adjusted by close monitoring of TSH

levels• T4 requirements- relatively great during first

year of life• High circulating T4 level is usually needed to

normalize TSH• Early treatment with T4 results in normal IQ

levels

Page 33: Thyroid pharmacology

Hyperthyroidism

• Excessive thyroid function

Thyrotoxicosis• State of thyroid hormone excess

Major etiologies of thyrotoxicosis• Hyperthyroidism caused by Graves' disease• Toxic multinodular goiter• Toxic adenomas

Page 34: Thyroid pharmacology

TreatmentHyperthyroidism of Graves' disease is treated by reducing

thyroid hormone synthesis• Antithyroid drugs• Reducing the amount of thyroid tissue with radioiodine (131I)• Subtotal thyroidectomy

No single approach is optimal and that patients may require multiple treatments to achieve remission.

Antithyroid drugs are the predominant therapy in many centers in Europe and Japan

Radioiodine is more often the first line of treatment in North America

Page 35: Thyroid pharmacology

ANTITHYROID DRUGS (Drugs used in hyperthyroidism)

• Thioamides (reduce the synthesis of thyroid hoemones)

– Carbimazole– Methimazole– Propylthiouraciliodide

• Radioactive iodine (I131)• Iodide ( high doses) • Ionic inhibitors (inhibit iodide uptake) - use is obsolete due to toxicity

– Thiocyanates– Perchlorates– Nitrates

• Propranolol - Adjunct therapy in thyrotoxicosis

Page 36: Thyroid pharmacology

Thioamides• Mechanism

– reduce the synthesis of thyroid hormones by inhibiting iodination of tyrosine and coupling of iodotyrosine to form T3 and T4

• Clinical use– Carbimazole

• Graves disease-till remission of symptoms (30-60mg) maintenance dose(5-15mg)

– Propylthiouracil (300-450 mg/d orally) maintenance dose (50-150 mg/d)

• Nodular toxic goiter• Prior to surgery for hyperthyroidism• With radioactive iodine to decrease symptoms before

radiation effects are manifested• Adverse effects

– Hypothyroidism– Vasculitis, agranulocytosis, Hypoprothrombinaemia– Cholestatic jaundice – Hair pigmentation

Page 37: Thyroid pharmacology

Iodides

• Mechanism – Selectively trapped by the thyroid gland (uptake being

increased in hyperthyroidism and reduced in hypothyroidism).– Large doses inhibit secretion of thyroid hormones by inhibition

of thyroglobulin proteolysis– Induce involution and decrease vascularity of the gland.

• Clinical use• Preoperative use in thyroid surgery(Potassium iodide, 60

mg orally thrice daily) • Thyroid crisis • Accidental over dosage of radioactive iodine (to protect

the thyroid follicles)• Prophylactic use in endemic goiter. Added to salt (1 in

100,000 parts )as iodized salts.• As an expectorant, antiseptic for topical use

Page 38: Thyroid pharmacology

Adverse effects- Thioamides

• maculpapular pruritic rash • murticarial rash• Arthralgia• Lymphadenopathy• lupus-like syndrome• Polyserositis

Page 39: Thyroid pharmacology

• Adverse reactions

– Acute hypersensitivity reactions (angioneurotic oedema, skin haemorrage, drug fever)

– salivation, lacrimation, soreness of throat, conjunctivitis, coryza-like symptoms, skin rashes

– Foetal or neonatal goiter

Page 40: Thyroid pharmacology

Radiioactive iodine

• Mechanism of action

– Trapped by the thyroid follicles and incorporated into thyroglobulin

– Emits both beta and gamma rays(half-life 8 days)

– Beta rays - short range and act on thyroid tissue only

– The gamma rays are more penetrative and can be detected by Gieger counter for diagnostic use.

Page 41: Thyroid pharmacology

Clinical Use

• Radioactive sodium iodide (5-8 m curie) orally.

• Grave’s disease, including relapse after subtotal thyroidectomy.

• Toxic nodular goiter

• Thyroid carcinoma

• Diagnosis of thyroid function . 50-100 micro curie is administered.

• best in patients over 35 years and in the presence of cardiac disease

• Clinical response is slow and may take 6-12 weeks for suppression of hyperthyroid symdrome

Page 42: Thyroid pharmacology

Effects of drugs on thyroid functions Drugs. Effect

Dopamine, l-dopa, corticosteroids, somatostatin

Inhibition of TRH and TSH secretion.

Iodides, lithium. Inhibition of thyroxine synthesis, and hypothyroidism

Cholestyramine, colestipol, sucralfate, aluminium salts

Inhibit thyroxine absorption from gut

Phenytoin, carbamazepine, rifampicin, phenobarbitone

Enzyme induction. May enhance T3 and T4 metabolism

Propylthiouracil, amiodarone Inhibit conversion of T4 to T3

corticosteroids, beta-blockers Androgens, glucocorticoids,

Decrease thyroxine-binding globulin

Oestrogens, tamoxifen, mitotane Increase thyroxine-binding globulin

Salicylates, mefenamic acid, furosemide

Displace T3 and T4 from thyroxine –binding globulin.